Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 398 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertrophic Clear all
Recruiting Phase 2 Interventional

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

NCT06345495
View directory record Official record
Conditions
Splenomegaly, Myelofibrosis
Interventions
Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam, Eltrombopag, Busulfan, Romiplostim, Fludarabine phosphate, Cyclophosphamide, Mesna, Tacrolimus
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Nov 9, 2026, 5:29 AM EST
Completed Phase 2 Interventional

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

NCT01912534
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Valsartan, Placebo
Drug
Lead sponsor
Carelon Research
Other
Eligibility
8 Years to 45 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Stanford, California • Aurora, Colorado • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Nov 9, 2026, 5:29 AM EST
Completed No phase listed Observational

Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)

NCT01873963
View directory record Official record
Conditions
Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
Not listed
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
11
States / cities
Aurora, Colorado • Miami, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Nov 9, 2026, 5:29 AM EST
Recruiting Phase 4 Interventional

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

NCT06941870
View directory record Official record
Conditions
Factor VIII Deficiency
Interventions
Efanesoctocog alfa
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 9, 2026, 5:29 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Daily Doses of Rice or Whey Protein on Resistance Training Adaptations

NCT04411173
View directory record Official record
Conditions
Hypertrophy
Interventions
Whey Protein
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Nov 9, 2026, 5:29 AM EST
Completed Not applicable Interventional Results available

Effectiveness of Pressure Garment Therapy After Burns

NCT01005732
View directory record Official record
Conditions
Hypertrophic Scarring After Burn Injury
Interventions
Custom fabricated pressure garments
Device
Lead sponsor
University of Washington
Other
Eligibility
7 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 4, 2011 · Synced Nov 9, 2026, 5:29 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

AV-23-001 AVAVA MIRIA Pilot Study

NCT06557434
View directory record Official record
Conditions
Wrinkle, Acne Scars - Mixed Atrophic and Hypertrophic, Pigmented Lesions, Skin Laxity, Scars
Interventions
MIRIA
Device
Lead sponsor
AVAVA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Dix Hills, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Nov 9, 2026, 5:29 AM EST
Completed No phase listed Observational

Study of Muscle Abnormalities in Patients With Specific Genetic Mutations

NCT00001871
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Muscular Dystrophy, Oculopharyngeal
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 9, 2026, 5:29 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Resistance Training and Blood Flow Restriction

NCT04938947
View directory record Official record
Conditions
Blood Flow Restriction and Low-Intensity Resistance Training
Interventions
Blood Flow Restriction Cuffs, Low-Intensity Resistance Training, High-Intensity Resistance Training
Device · Other
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 30 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lawrence, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Nov 9, 2026, 5:29 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06253221
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
Mavacamten, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Nov 9, 2026, 5:29 AM EST
Completed Phase 1 Interventional Results available

Hypertrophic Regression With N-Acetylcysteine in HCM

NCT01537926
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Nov 9, 2026, 5:29 AM EST
Terminated No phase listed Observational

Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients

NCT01427374
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
University of Alberta
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Nov 9, 2026, 5:29 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)

NCT03310684
View directory record Official record
Conditions
Pediatric Disorder, Pediatric Obesity, Primary Hypertension
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
5 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Nov 9, 2026, 5:29 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Environmental Costs of Building Human Muscle

NCT06733857
View directory record Official record
Conditions
Greenhouse Gas Emissions, Water Use, Land Use
Interventions
VEG2, OMNI2
Behavioral
Lead sponsor
Game Changers Institute
Other
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Laguna Niguel, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Nov 9, 2026, 5:29 AM EST
Terminated No phase listed Observational

Genetic Predictors of Outcome in HCM Patients

NCT00156429
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Nov 9, 2026, 5:29 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers

Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy

NCT07147166
View directory record Official record
Conditions
Gender Dysphoria, Mastectomy, Hypertrophic Scar
Interventions
Brijjit® BP100-6 and BP-75, Control: Standard of care and normal wound dressing
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
19 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 9, 2026, 5:29 AM EST
Completed Not applicable Interventional

A Study to Determine the Safety and Efficacy of a New Non-invasive Heating Garment to Reduce Urinary Hesitancy

NCT00700505
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH), Urinary Retention, Urinary Hesitancy Intermittent
Interventions
FlowPants(R) Garment
Device
Lead sponsor
ThermaRx, Inc.
Industry
Eligibility
25 Years to 80 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2012 · Synced Nov 9, 2026, 5:29 AM EST
Terminated Phase 2 Interventional Results available

An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

NCT05011058
View directory record Official record
Conditions
Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related PTLD, EBV-Related Lymphoproliferative Disorder
Interventions
Nanatinostat in combination with valganciclovir
Drug
Lead sponsor
Viracta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
17
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Nov 9, 2026, 5:29 AM EST
Recruiting No phase listed Observational

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

NCT06023186
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten
Drug
Lead sponsor
Michael Ayers
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Nov 9, 2026, 5:29 AM EST
Completed No phase listed Observational

Hypertrophic Scarring After Facial Burn

NCT00242970
View directory record Official record
Conditions
Burn
Interventions
3-Dimensional Color Scanning
Device
Lead sponsor
Legacy Health System
Other
Eligibility
4 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Nov 9, 2026, 5:29 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Prophylactic Ethanol Lock Therapy (ELT) in Patients on Home Parenteral Nutrition

NCT02227329
View directory record Official record
Conditions
Catheter-related Bloodstream Infection (CRBSI) Nos, Bloodstream Infection Due to Central Venous Catheter, Bloodstream Infection Due to Hickman Catheter
Interventions
Ethanol, Heparin Lock, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Nov 9, 2026, 5:29 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Laser Treatment for the Improvement of Scars and Scleroderma

NCT04567537
View directory record Official record
Conditions
Scars, Scleroderma
Interventions
Laser Treatment
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Nov 9, 2026, 5:29 AM EST
Withdrawn Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy

NCT01556568
View directory record Official record
Conditions
Cardiomegaly
Interventions
MEK162
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Nov 9, 2026, 5:29 AM EST
Not listed Not applicable Interventional

Activity Dependent Rehabilitation Model to Improve Bone and Muscle Outcomes

NCT02309983
View directory record Official record
Conditions
Disuse Osteoporosis, Atrophy, Disuse, Nervous System, Structural; Marker, Skeletal Muscle Hypertrophy
Interventions
Electrical Stimulation, Stand Retraining with Body Weight Support (BWS)
Other
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 58 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Nov 9, 2026, 5:29 AM EST